Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-011-6 | CAS number: 131-11-3
Carcinogenicity
Administrative data
Description of key information
DMP did neither initiate nor promote cancer in a 1-year study in male CD-1 mice (NTP, 1993).
Key value for chemical safety assessment
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 2 700 mg/kg bw/day
- Study duration:
- chronic
- Species:
- mouse
Justification for classification or non-classification
GHS classification (GHS UN rev.2, 2007): no classification required
Additional information
DMP-Carcinogenicityin vivo, Initiation/promotion study
DMP was tested in male CD-1 mice [NTP, 1993] for one year with one dose of 0.1 ml (calculated 2700 mg/kg bw; density=1.194g/ml). Neat substance was applied dermally on clipped skin over one year. In parallel DMBA (7,12-dimethylbenz(a)anthracene) and TPA (12-O-tetradecanoylphorbol-13-acetat) were used as positive controls for initiation and promotion, respectively. Combined treatment of DMBA and TPA lead to an increase of both squamous cell papillomas and squamous cell carcinomas. All TPA-dosed groups had significantly greater incidences of dermal acanthosis, ulceration, exudation, and hyperkeratosis than controls. Therefore the TPA exposure concentration was adjusted to 0.025 mg/ml (2x per week) from week 10 on (starting concentration: 0.05 mg/ml 3x per week).DMP treatment had no effect on body weight compared to vehicle controls.Incidences of neoplasms in the DMP treated mice (initiation) were similar to vehicle controls. Thus, DMP was not able to initiate skin carcinogenesis when chronically promoted by TPA. Furthermore, DMP did not promote skin carcinogenesis in skin initiated with DMBA. The test substance is not carcinogenic, nor does it initiate and/or promote cancer.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
